CGM software development covers the full digital stack that turns a continuous glucose monitor into a connected medical device — sensor firmware, secure pairing, mobile applications, cloud infrastructure, clinician dashboards, and the regulatory documentation that enables it all to ship.
The global CGM market is on track to grow from USD 4.97 billion in 2024 to USD 9.93 billion by 2034 at a 7.22% CAGR — and the hardware companies winning that growth are the ones who solved the software side early.
This guide covers what CGM hardware companies need to know about software partners, the technology trends driving 2026 development priorities, the regulatory pathways in the US and EU, and how Platform-as-a-Service models like NEX can cut months off the time to clearance.
What CGM Hardware Companies Need to Know About Software in 2026
Most CGM hardware companies underestimate the software side of the product until late in development — at which point software becomes the bottleneck for FDA clearance, the cost overrun nobody planned for, and the technical debt that haunts every release for years. The global CGM market is growing fast enough that hardware companies have a window to ship; the companies that miss it are the ones that treated software as the last 20% of the project rather than the first 50%.
Three decisions shape the timeline more than any others:
Build vs. buy the software platform
Building from scratch — companion apps, clinician dashboards, cloud infrastructure, secure pairing, regulatory documentation — typically adds 6 to 12 months before clinical features even begin. Platform-as-a-Service models compress this dramatically.
In-house team vs. specialist software partner
Most hardware teams are excellent at hardware. Regulated medical software is a different discipline — IEC 62304 lifecycle, ISO 13485 QMS, ISO 14971 risk management, FDA cybersecurity premarket. Building this competency in-house takes years.
Regulatory strategy mapped before architecture
FDA pathway (510(k) vs De Novo), risk class, predicate device research, and cybersecurity submission requirements (FDA section 524B) all shape the architecture. Mapping the regulatory strategy after building the software is where most hardware companies lose 6–12 months to rework.
The rest of this guide covers the market trajectory that makes CGM a strategic priority, the software trends shaping 2026 development, the regulatory pathways in the US and EU, and how PaaS models like NEX let hardware companies inherit the regulatory groundwork rather than recreate it.
The Global CGM Market in Numbers — Why Timing Matters for Hardware Companies
The global continuous glucose monitoring market reached USD 4.97 billion in 2024 and is projected to reach USD 9.93 billion by 2034, growing at a 7.22% compound annual growth rate. Three forces are driving the growth: rising Type 2 diabetes prevalence, growing demand for non-invasive sensor formats, and the expansion of CGM beyond insulin-dependent populations into pre-diabetic and wellness markets.
Regional Dynamics
North America holds the largest share at over 38% of the global CGM market in 2024, driven by high diabetes prevalence, established CMS reimbursement (which now covers RT-CGM and isCGM for non-intensive insulin users), and early adoption of digital health platforms.
Asia-Pacific is the fastest-growing region, with rapid expansion driven by the diabetes burden in India and China, aging populations, and government-led digital health initiatives. Local manufacturing and regulatory modernization are improving market accessibility.
Europe offers strong reimbursement in Germany, the Netherlands, and Nordic markets, but variable coverage elsewhere — meaning EU market entry typically requires country-specific reimbursement strategies.
Technology Adoption Trends
RT-CGM and isCGM remain the dominant device categories, but wearable and patch-based CGMs are gaining share due to comfort and form factor advantages. Remote patient monitoring is accelerating CGM adoption in home healthcare. The largest underserved segment is non-insulin-dependent users — pre-diabetics, gestational diabetics, and wellness-focused users — where consumer-facing CGM products are growing fastest.
For hardware companies, the implication is clear: the market window is open, but it’s increasingly competitive. Companies that ship in 2026–2027 have the strongest growth trajectory; companies still in development through 2028 face an established competitor set.
Key Opportunities for Device Developers
As the global CGM market accelerates globally, medical device innovators have a unique opportunity to lead the next wave of diabetes care. From hardware breakthroughs to software ecosystems, several trends are opening new value streams for developers of connected medical devices and digital health solutions.
Non-Invasive CGM Technologies
Non-invasive continuous glucose monitoring is one of the most anticipated advancements in the global CGM market.
- Next-Gen Comfort – Traditional CGMs rely on subcutaneous sensors, which can cause discomfort or skin irritation. Non-invasive CGMs eliminate the need for skin penetration by using advanced biosensor technologies like:
- Near-Infrared (NIR) Spectroscopy
- Raman Spectroscopy
- Electromagnetic Sensing
- Wearable Formats – Developers are embedding these sensors into wristbands and smartwatches, offering seamless, skin-friendly glucose tracking.
Market Potential
Non-invasive CGM technologies have strong market potential by significantly improving user comfort and reducing adoption barriers. These systems are expected to drive greater adherence and acceptance among users, particularly those who find traditional sensors uncomfortable or intimidating. Their painless, skin-friendly design makes them especially appealing to pediatric and elderly populations, as well as individuals who are needle-averse.
Additionally, non-invasive CGMs are poised to expand adoption beyond insulin-dependent diabetics, reaching pre-diabetic individuals and wellness-focused users seeking proactive glucose monitoring as part of a broader health strategy.
Challenges and Opportunities
Non-invasive CGM technologies still face challenges, particularly around signal interference and the need for precise calibration. However, ongoing advancements in sensor materials and the application of machine learning algorithms are steadily improving the accuracy and reliability of these systems.
For device developers, this represents a critical window of opportunity. Those who invest early in non-invasive CGM research and development can secure a leading position in what promises to be a transformative shift in diabetes management.
Digital Health Integration
The convergence of CGM devices with digital health platforms is reshaping how glucose data is used for treatment, engagement, and long-term health outcomes.
- Cloud-based ecosystems – CGM systems are increasingly integrating with:
- Integration allows for smart features that add value, including:
- Real-time alerts for hypo/hyperglycemia
- Predictive insights and trend analysis
- Personalized treatment recommendations
Benefits for Developers
Integrating CGM devices with digital health platforms offers several strategic advantages for developers. It enhances user engagement and increases device stickiness by providing real-time insights and personalized support that encourage consistent use.
This integration also opens the door to creating hybrid software and hardware solutions that deliver a seamless user experience. Additionally, it enables the development of new revenue models centered on data services, mobile app subscriptions, and clinician-facing dashboards, creating ongoing value beyond the initial device sale.
Compliance and Security
As CGM systems become more connected and data-driven, developers must prioritize compliance with data privacy regulations such as HIPAA in the US and GDPR in the EU. These laws mandate the secure handling of sensitive health information, making robust data protection and user consent protocols essential.
Additionally, software interoperability is critical for integrating CGM solutions into hospital systems, telehealth platforms, and payer networks. Seamless data exchange not only supports clinical workflows but also enhances the overall value and adoption of CGM technologies in modern healthcare ecosystems.
What Modern CGM Apps Include — Standard and Differentiating Features
For CGM hardware companies evaluating their software roadmap, knowing what modern CGM apps must include — and what differentiates the leaders — is a starting point for product strategy. The features below are split into two categories: standard capabilities that have become table stakes for any commercial CGM app, and differentiating capabilities that distinguish leading apps from the rest.
Standard CGM App Features
These features represent the baseline expectations for any modern CGM app. Users and regulators expect them; competitors offer them. Hardware companies entering the market need to plan for all of them.
- Real-time glucose monitoring — continuous display of glucose levels updated every few minutes, with color-coded trend indicators showing rising, falling, or stable patterns.
- Customizable alerts and notifications — configurable high and low glucose thresholds, predictive alerts based on trend data such as rapid drops, and alerts that notify caregivers in addition to the patient.
- Historical data and trend analysis — graphs showing glucose levels over hours, days, weeks, and months; data export for clinical review; time-in-range summaries; average glucose readings; and pattern identification.
- Data sharing capabilities — real-time data sharing with caregivers, family members, and healthcare providers; integration with provider portals or remote patient monitoring platforms.
- Cross-platform mobile accessibility — native iOS and Android applications; automatic cloud backup and syncing across devices; support for paired wearables such as Apple Watch.
- Integration with other health data — syncing with fitness trackers and digital health platforms; optional logging of meals, insulin doses, and physical activity for context.
Differentiating CGM App Features
These features go beyond the baseline and distinguish leading CGM apps from the rest. Hardware companies competing on software differentiation typically invest in two or three of these areas — chosen based on the patient population, the clinical workflow, and the regulatory pathway the device is targeting.
- Predictive and AI-driven insights — machine learning models that forecast glucose trends in advance, helping users take preemptive action before levels become dangerous. PCCP-eligible under FDA AI/ML guidance.
- Personalized coaching and recommendations — AI-powered tips, gamified feedback, and in-app coaching that improve time-in-range and reinforce healthy habits. Adjusts recommendations based on individual behavior patterns.
- Automated insulin dosing integration — integration with automated insulin delivery systems for hybrid closed-loop or fully closed-loop diabetes management. Subject to additional FDA scrutiny, but a significant clinical differentiator.
- Community and social features — built-in support communities, peer insights, and shared experience features that increase engagement and reduce isolation. Particularly valuable for newly-diagnosed patients.
- Multi-device data aggregation — support for importing data from multiple CGM systems, insulin pumps, and activity trackers into a unified dashboard. Useful for clinicians managing diverse patient populations.
- Advanced visualization and reporting — dynamic charts, annotation features, and clinically-formatted reports that make data interpretation easier for both patients and providers. High value for clinical workflow integration.
For hardware companies, the practical question isn’t whether to include standard features — those are table stakes — but which differentiating features to invest in first and how those investments fit within the regulatory class the product targets. AI-driven insights and automated dosing integration carry additional FDA scrutiny but justify it through clinical impact. Coaching, community, and visualization features are typically lower-risk additions that improve engagement without changing the regulatory pathway.
Platform-as-a-Service for CGM Hardware Companies
Platform-as-a-Service (PaaS) for medical devices is software infrastructure — companion apps, dashboards, cloud, regulatory documentation — built once and customized per product, rather than rebuilt from scratch for every new device. For CGM hardware companies, the PaaS model can compress development by 6 to 12 months and meaningfully reduce regulatory risk.
What a CGM PaaS Includes
A purpose-built CGM PaaS — like Sequenex’s NEX Platform — typically includes prebuilt iOS and Android companion apps, patient and clinician dashboards, an administrator portal, secure cloud infrastructure for medical data, BLE pairing infrastructure, OTA firmware update support, and the regulatory documentation framework (IEC 62304 lifecycle artifacts, ISO 14971 risk files, ISO 13485 QMS process records) that wraps around the engineering work.
Why Hardware Teams Choose PaaS Over In-House Build
Time to clearance. Building the regulated software stack from scratch takes 6 to 12 months before clinical features begin. PaaS removes that block.
Inherited regulatory groundwork. PaaS infrastructure built inside an ISO 13485-certified QMS means the buyer inherits the QMS process — not just the code. Software developed inside a certified QMS faces a much shorter path through FDA review.
Compliance-ready data layer. HIPAA, GDPR, FHIR/HL7 integration, audit logging, RBAC — table stakes for any CGM connected to clinicians, but expensive and time-consuming to build correctly. PaaS provides them as the default.
Engineering focus on hardware differentiation. PaaS frees the hardware team to focus on what they’re best at: sensor performance, form factor, accuracy, calibration. Software stops being the bottleneck.
B2B and B2B2C Flexibility
PaaS models support both white-labeled OEM deployments — where the hardware company delivers a branded CGM ecosystem to clinicians and patients — and B2B2C distribution where digital health platforms or pharma partners license the software around the hardware. Subscription, API access, and cloud hosting create recurring revenue alongside the hardware sale.
See How NEX Accelerates CGM Development
Technology Trends Shaping 2025 and Beyond
The global CGM market in 2025 is being reshaped by a wave of cutting-edge innovations that are improving usability, accuracy, and integration across healthcare systems. For developers of connected medical devices, understanding these trends is essential to staying competitive and delivering patient-centered solutions.
RT-CGM and isCGMs
One of the most significant advances in continuous glucose monitoring technology is the widespread adoption of real-time CGM systems. These devices offer continuous, dynamic glucose readings and customizable alerts, allowing patients and clinicians to respond proactively to glycemic fluctuations.
RT-CGMs are increasingly favored for their ability to deliver deeper insights into glucose trends, support tight glycemic control, and reduce emergency events. Longer sensor lifespans, reduced calibration needs, and enhanced app connectivity are making these systems more accessible and appealing to a wider user base.
Intermittently scanned CGMs, also known as flash glucose monitors, are gaining popularity, especially among individuals with Type 2 diabetes. These devices provide continuous glucose data but require manual scanning to access readings. CGMs are valued for their affordability, minimal invasiveness, and simplified user experience, which make them attractive to both healthcare providers and patients seeking cost-effective alternatives.
Wearable and Patch-Based CGMs
Another major trend in the 2025 global CGM market is the rise of wearable and patch-based CGMs, which integrate all essential components—sensor, transmitter, and memory—into a discreet, adhesive-backed unit. These compact systems offer a seamless user experience and align closely with consumer expectations for modern health tech.
Designed for active lifestyles, they appeal to younger users and those prioritizing comfort, aesthetics, and convenience. Many are now compatible with smartphones and smartwatches, further enhancing usability.
Digital Health Platforms and AI Integration
Integration with digital health platforms and artificial intelligence is also transforming how CGM data is used. Cloud-based connectivity allows for remote patient monitoring, while AI-driven analytics enable predictive alerts and personalized recommendations.
This evolution supports closed-loop insulin delivery systems and the broader vision of an automated, intelligent diabetes management ecosystem.
Regulatory Landscape: Navigating Compliance
For developers in the global CGM market, navigating the global regulatory environment is as critical as designing accurate, connected medical devices. Each major region presents a unique set of standards, requirements, and opportunities. Understanding the regulatory landscape helps developers ensure timely approvals, avoid costly setbacks, and maintain user trust, especially as CGM systems increasingly integrate with digital health platforms and AI-powered decision tools.
United States: Streamlined Pathways and Favorable Reimbursement
The U.S. remains one of the most attractive markets for CGM device developers due to its structured, innovation-friendly regulatory framework. The Food and Drug Administration (FDA) classifies CGM devices under Class II or III, requiring either 510(k) clearance or Premarket Approval depending on the system’s complexity and intended use.
Key U.S. advantages include:
- Clear guidance on interoperability and cybersecurity for devices that integrate with insulin pumps or mobile apps
- Supportive reimbursement environment via the Centers for Medicare & Medicaid Services (CMS), which now covers both RT-CGM and isCGM for broader patient groups, including non-intensive insulin users
- Faster time to market for developers who align early with FDA expectations for accuracy, safety, and data security
FDA Cybersecurity Premarket Requirements (Section 524B)
Since 2023, FDA premarket submissions for connected medical devices — including CGMs — must include detailed cybersecurity documentation under section 524B of the Federal Food, Drug, and Cosmetic Act. Required content includes a Software Bill of Materials (SBOM), threat modeling, vulnerability assessment, and a plan for monitoring and addressing post-market vulnerabilities. CGM submissions that fail to meet 524B requirements face refusal-to-accept (RTA) decisions — meaning the submission doesn’t progress to substantive review until the cybersecurity package is complete. Building cybersecurity into architecture from sprint zero, rather than retrofitting it before submission, is the practical way to avoid RTA delays.
European Union: MDR and GDPR Compliance
In the EU, the regulatory environment is shaped by two powerful frameworks—the Medical Device Regulation (MDR) and the General Data Protection Regulation (GDPR). Both are essential to address when developing CGM systems for the European market.
Important considerations include:
- MDR enforces stricter clinical evaluation and risk classification, increasing regulatory costs and approval timelines
- All CGM devices must obtain CE marking through a Notified Body, with rigorous post-market surveillance requirements
- GDPR mandates robust data privacy measures, particularly for cloud-connected CGMs that transmit sensitive health data
- While markets like Germany and the Netherlands offer strong reimbursement policies, others vary significantly by country, requiring localized strategies
Despite these hurdles, MDR compliance is seen as a competitive advantage that assures patients and clinicians of product safety and performance.
Asia-Pacific: Growing Demand Meets Regulatory Fragmentation
The Asia-Pacific CGM market is the fastest-growing globally, offering major opportunities but also presenting regulatory complexity. Several countries are modernizing their health tech frameworks, but processes remain fragmented.
Key regional insights:
- Japan (PMDA) and Australia (TGA) have well-aligned standards with global norms, requiring thorough clinical validation
- China’s NMPA mandates domestic clinical trials and longer review timelines, creating barriers for foreign entrants
- India’s CDSCO is evolving toward harmonized regulation but remains bureaucratic and slow
- South Korea stands out for embracing digital health integration and offering faster pathways for CGM and remote monitoring devices
For developers, the Asia-Pacific region demands country-specific regulatory strategies, with a growing emphasis on connected care, especially in urban and aging populations.
Key Compliance Considerations Across the Global CGM Market
No matter the region, several regulatory themes are universally critical for developers entering or expanding in the global CGM market:
- Cybersecurity: Devices that connect to mobile apps or cloud platforms must demonstrate protection against data breaches and unauthorized access.
- Data Privacy: Compliance with HIPAA, GDPR, and regional equivalents is essential for any CGM that collects and transmits personal health information.
- Clinical Validation: Regulatory bodies expect robust, real-world data on accuracy, reliability, and patient safety, particularly for non-invasive and AI-enhanced systems.
- Interoperability: Increasingly, regulators value CGMs that can integrate seamlessly with insulin pumps, EHRs, and telehealth platforms.
As the global CGM market regulatory landscape evolves, developers must design with compliance in mind from the start. By aligning their strategies with regional frameworks and global best practices, innovators can bring transformative CGM solutions to market faster and with greater long-term success.
Strategic Considerations for Developers
As the global CGM market evolves rapidly through technological innovation and digital transformation, medical device developers must adopt a strategic, future-focused approach to product development. From platform integration to regulatory readiness and market positioning, several factors can determine success in an increasingly competitive landscape.
1. Build for Interoperability and Integration
Today’s CGM systems are no longer stand-alone devices—they are integral components of larger connected medical ecosystems.
- Ensure interoperability with EHRs, telemedicine platforms, and insulin delivery systems.
- Support Bluetooth Low Energy (BLE) and API-based integrations for seamless data flow across devices and care platforms.
- Align with global trends toward closed-loop insulin delivery and AI-powered decision support, which rely heavily on reliable CGM data streams.
2. Prioritize User Experience and Engagement
Designing for usability is just as important as technical performance in the modern global CGM market.
- Invest in intuitive mobile apps and user interfaces that simplify data visualization and trend tracking.
- Incorporate predictive analytics, real-time alerts, and behavioral insights to empower users and improve adherence.
- Target comfort, discreteness, and durability, especially for wearable, patch-based, and non-invasive CGMs.
3. Embrace Platform-as-a-Service Models
Developers, especially startups and OEMs, can reduce time-to-market and development risk by leveraging PaaS offerings, such as Sequenex’s NEX platform, tailored to CGM and biosensor technologies.
- Use prebuilt infrastructure for data ingestion, cloud storage, CRM tools, and regulatory compliance.
- Focus internal resources on sensor R&D while outsourcing core digital capabilities.
- Consider white-label software to support both B2B and B2B2C deployment models, enabling scalable, flexible go-to-market strategies.
4. Align with Value-Based Care Models
Healthcare systems worldwide are shifting toward value-based care, emphasizing outcomes over procedures.
- Highlight how your CGM solution supports better glycemic control, fewer complications, and reduced hospitalizations.
- Offer analytics that provide clinician-facing dashboards and population health insights to help providers manage diabetes more effectively.
- Build tools that integrate with RPM workflows to enhance reimbursement potential and long-term adoption.
5. Plan Early for Regulatory and Reimbursement Strategy
Bringing a new CGM device to market requires more than technical innovation—it demands proactive compliance and payer alignment.
- Address cybersecurity, data privacy, and clinical validation during the design phase.
- Understand region-specific requirements, including FDA 510(k)/PMA, EU MDR, and Asia-Pacific market access pathways.
- Work with reimbursement experts to ensure coverage for your solution under CMS, private insurers, or national health programs, especially in emerging markets.
In a competitive and fast-moving global CGM market, strategic alignment across software, hardware, and healthcare delivery is essential. Developers who focus on interoperability, user-centric design, and platform-based scalability will be best positioned to lead the next generation of continuous glucose monitoring innovations.
Frequently Asked Questions About CGM Software Development
What is CGM software development?
CGM software development is the engineering of the digital stack that turns a continuous glucose monitor into a connected medical device — sensor firmware, secure Bluetooth or cellular pairing, native iOS and Android companion apps, HIPAA-compliant cloud infrastructure, clinician dashboards, and the regulatory documentation that supports FDA clearance. Most CGM products on the market today rely on dozens of integrated software components, all of which must be developed under IEC 62304, ISO 13485, and ISO 14971.
How long does CGM software development take?
CGM software development from scratch — including companion apps, cloud infrastructure, regulatory documentation, and FDA premarket submission — typically takes 18 to 30 months for hardware companies starting fresh. Teams using a Platform-as-a-Service model like Sequenex’s NEX Platform often cut that by 6 to 12 months by inheriting the regulatory groundwork rather than rebuilding it.
What FDA pathway do CGMs use?
Most CGMs reach the U.S. market through 510(k) premarket notification, demonstrating substantial equivalence to a legally marketed predicate. Novel CGMs without a clear predicate — including non-invasive CGMs and AI-integrated systems — typically use the De Novo classification pathway. High-risk CGMs requiring extensive clinical trial data may use Premarket Approval (PMA). All three pathways require FDA cybersecurity documentation under section 524B.
Should a CGM hardware company build software in-house or partner?
For most CGM hardware companies, partnering with a specialist medical device software firm is faster and lower-risk than building in-house. Regulated medical device software requires compliance with IEC 62304 (software lifecycle), ISO 13485 (quality management system), ISO 14971 (risk management), and FDA cybersecurity guidance — disciplines that are different from sensor and hardware engineering and take years to build internally. The math typically favors partnership unless software is the company’s primary differentiator.
What is a Platform-as-a-Service for CGM development?
A CGM Platform-as-a-Service is prebuilt, customizable software infrastructure — typically companion apps, dashboards, cloud, and regulatory documentation — engineered once inside a certified medical device QMS and adapted to each hardware client. PaaS models like Sequenex’s NEX Platform compress CGM development time and reduce regulatory risk because the buyer inherits both the code and the underlying QMS process certification.
What standards govern CGM software development?
CGM software development is governed by IEC 62304 (medical device software lifecycle processes), ISO 13485 (medical device quality management system), and ISO 14971 (medical device risk management). FDA-regulated CGMs additionally follow 21 CFR Part 820 design controls and FDA section 524B cybersecurity premarket requirements. EU CGMs follow the Medical Device Regulation (MDR) and EN 62304. International market access typically follows IMDRF-harmonized expectations.
Capitalizing on the Global CGM Market Momentum
As we move through 2025, the global CGM market stands at the crossroads of innovation, regulation, and rising demand. Developers of connected medical devices are uniquely positioned to shape the future of diabetes care by leveraging advancements in biosensors, AI integration, and digital health platforms. Non-invasive technologies, cloud-based ecosystems, and PaaS solutions—like Sequenex’s NEX—are redefining what’s possible in continuous glucose monitoring.
But opportunity comes with complexity. Success in the global CGM market will depend on strategic alignment with user needs, regional regulations, and healthcare delivery models. Those who prioritize interoperability, security, regulatory readiness, and user experience will not only accelerate time to market, but they’ll also define the next generation of life-changing CGM technologies.
